Pfizer Inc. (NYSE:PFE) Shares Sold by Bremer Bank National Association

Share on StockTwits

Bremer Bank National Association cut its position in shares of Pfizer Inc. (NYSE:PFE) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,328 shares of the biopharmaceutical company’s stock after selling 3,912 shares during the quarter. Bremer Bank National Association’s holdings in Pfizer were worth $2,948,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of PFE. State Street Corp raised its holdings in shares of Pfizer by 0.3% in the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after acquiring an additional 830,299 shares during the last quarter. Maverick Capital Ltd. acquired a new position in shares of Pfizer in the first quarter worth $297,000. APG Asset Management N.V. raised its holdings in shares of Pfizer by 129.4% in the first quarter. APG Asset Management N.V. now owns 6,955,829 shares of the biopharmaceutical company’s stock worth $227,038,000 after acquiring an additional 3,924,241 shares during the last quarter. Pathstone Family Office LLC acquired a new position in shares of Pfizer in the first quarter worth $131,000. Finally, Cox Capital Mgt LLC raised its holdings in shares of Pfizer by 4.1% in the second quarter. Cox Capital Mgt LLC now owns 54,196 shares of the biopharmaceutical company’s stock worth $1,772,000 after acquiring an additional 2,133 shares during the last quarter. 69.08% of the stock is owned by hedge funds and other institutional investors.

PFE stock traded up $0.75 during trading on Friday, reaching $38.18. 28,992,325 shares of the stock traded hands, compared to its average volume of 20,809,482. The business’s 50 day moving average price is $36.59 and its 200-day moving average price is $36.49. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $40.97. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. The firm has a market capitalization of $212.16 billion, a PE ratio of 15.15, a P/E/G ratio of 3.10 and a beta of 0.66.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm had revenue of $11.80 billion during the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter in the previous year, the business earned $0.80 earnings per share. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.84 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s payout ratio is 51.53%.

In related news, Director Ronald E. Blaylock bought 13,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.08% of the stock is owned by corporate insiders.

PFE has been the subject of a number of analyst reports. UBS Group boosted their price target on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Berenberg Bank initiated coverage on Pfizer in a research note on Tuesday, September 29th. They issued a “hold” rating and a $38.00 target price for the company. Morgan Stanley upped their target price on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Finally, Royal Bank of Canada set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research note on Friday, October 16th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average price target of $39.81.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: How can investors benefit from after-hours trading?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.